Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
ARWR Arrowhead Pharmaceuticals
34.750+1.470+4.42%
Trading Session
01/31 12:40 ET
High
34.885
Open
33.510
Turnover
8.62M
Low
33.510
Pre Close
33.280
Volume
249.89K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Q1 2023 EPS Estimates for Arrowhead Pharmaceuticals, Inc. Cut by HC Wainwright (NASDAQ:ARWR)
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating) – Equities research analysts at HC Wainwright decreased their Q1 2023 earnings estimates for shares of Arrowhead Pharmaceuticals in a rese
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 First Quarter Results
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) today announced that it will host a webcast and conference call on February 6, 2023, at 4:30 p.m. ET to discuss its financial results for the fiscal 2023 first quarter ended
Arrowhead Pharmaceuticals, Inc. Expected to Earn Q1 2023 Earnings of $0.16 Per Share (NASDAQ:ARWR)
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating) – Equities research analysts at SVB Leerink issued their Q1 2023 earnings per share estimates for Arrowhead Pharmaceuticals in a report is
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Short Interest Up 11.8% in December
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating) was the recipient of a significant increase in short interest in December. As of December 30th, there was short interest totalling 4,740,000
Analysts Offer Insights on Healthcare Companies: Aeterna Zentaris (AEZS), Arrowhead Pharmaceuticals (ARWR) and Enlivex (ENLV)
Investors Might Be Losing Patience for Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Increasing Losses, as Stock Sheds 8.3% Over the Past Week
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) shareholders have seen the share price descend 12% over the month. But that does not change the realty that the stock's performance has been terrific,
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stake Reduced by Dupont Capital Management Corp
Dupont Capital Management Corp reduced its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating) by 25.1% in the third quarter, according to the company in its most recent 13
Cantor Fitzgerald Biotech Analyst to Hold Analyst/industry Conference Call
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Average Recommendation of "Moderate Buy" by Brokerages
Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – Get Rating) have earned a consensus rating of "Moderate Buy" from the eleven research firms that are presently covering the stock, Marketbeat
Arrowhead Pharmaceuticals (ARWR) Receives a Buy From Robert W. Baird
Company Overview
More
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by R. Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
CEO： Dr. Christopher Anzalone,PhD
Market： NASDAQ
Listing Date： 06/16/1993
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet